+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Familial Adenomatous Polyposis - Pipeline Review, H2 2020

  • ID: 5146919
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 71 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ADT Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 8 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ADT Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • MORE
Introduction

Report Coverage
  • Familial Adenomatous Polyposis - Overview
  • Familial Adenomatous Polyposis - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
  • ADT Pharmaceuticals Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • Johnson & Johnson
  • Stemsynergy Therapeutics Inc
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
  • Zikani Therapeutics Inc
Familial Adenomatous Polyposis - Drug Profiles
(eflornithine hydrochloride + sulindac) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CLXONC-57 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FAPXIL SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • guselkumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Familial Adenomatous Polyposis - Dormant Projects
  • Familial Adenomatous Polyposis - Discontinued Products
  • Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Familial Adenomatous Polyposis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, H2 2020
  • Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2020
  • Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H2 2020
  • Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, H2 2020
  • Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, H2 2020
  • Familial Adenomatous Polyposis - Dormant Projects, H2 2020
  • Familial Adenomatous Polyposis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Familial Adenomatous Polyposis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • ADT Pharmaceuticals Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • Johnson & Johnson
  • Stemsynergy Therapeutics Inc
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
  • Zikani Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll